Biomarkers in Barrett's oesophagus

Biochemical Society Transactions

Volumn 38, Issue 2, 2010, Pages 343-347

  Huang, Qizhi ^a   Hardie, Laura J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Adenocarcinoma; Barrett's oesophagus; Biomarker; Screening; Surveillance; Therapy

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; PROTEIN P53; SURVIVIN; THYMIDYLATE SYNTHASE; TRASTUZUMAB; VASCULOTROPIN; PHARMACOLOGICAL BIOMARKER;

BARRETT ESOPHAGUS; CANCER CYTODIAGNOSIS; CANCER RISK; CHROMOSOME ABERRATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE COURSE; DNA METHYLATION; EPITHELIUM DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DISEASE; ESOPHAGUS DYSPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC MARKER; HETEROZYGOSITY LOSS; HUMAN; MINIMALLY INVASIVE PROCEDURE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PLOIDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK ASSESSMENT; SCREENING; TRANSCRIPTOMICS; TREATMENT OUTCOME; ANIMAL; GENETICS; MASS SCREENING; METABOLISM; METHODOLOGY; POPULATION; PROGNOSIS;

ANIMALS; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; DISEASE PROGRESSION; HUMANS; MASS SCREENING; POPULATION; PROGNOSIS;

EID: 77953273951     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0380343     Document Type: Review

References (50)

1. Wild, C.P. and Hardie, L.J. (2003) Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 3, 676-684
2. Jankowski, J.A. and Odze, R.D. (2009) Biomarkers in gastroenterology: between hope and hype comes histopathology. Am. J. Gastroenterol. 104, 1093-1096
3. Inadomi, J.M. (2009) Surveillance in Barrett's esophagus: a failed premise. Keio J. Med. 58, 12-18
4. Lao-Sirieix, P., Boussioutas, A., Kadri, S.R., O'Donovan, M., Debiram, I., Das, M., Harihar, L. and Fitzgerald, R.C. (2009) Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 58, 1451-1459
5. McManus, D.T., Olaru, A. and Meltzer, S.J. (2004) Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res. 64, 1561-1569
6. Pepe, M.S., Etzioni, R., Feng, Z.D., Potter, J.D., Thompson, M.L., Thornquist, M., Winget, M. and Yasui, Y. (2001) Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93, 1054-1061
7. McShane, L., Altman, D., Sauerbrei, W., Taube, S., Gion, M. and Clark, G. (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Exp. Oncol. 28, 99-105 (Pubitemid 44140259)
8. Pera, M. (2003) Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J. Surg. 27, 999-1008
9. Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E., Vieth, M., Stolte, M., Talley, N.J. and Agreus, L. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129, 1825-1831
10. Rygiel, A.M., Milano, F., ten Kate, F.J., de Groot, J.G., Peppelenbosch, M.P., Bergman, J.J. and Krishnadath, K.K. (2008) Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. Genes Chromosomes Cancer 47, 396-404
11. Shaheen, N.J., Crosby, M.A., Bozymski, E.M. and Sandler, R.S. (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119, 333-338
12. Maley, C.C., Galipeau, P.C., Li, X.H., Sanchez, C.A., Paulson, T.G. and Reid, B.J. (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 64, 3414-3427
13. Reid, B.J., Prevo, L.J., Galipeau, P.C., Sanchez, C.A., Longton, G., Levine, D.S., Blount, P.L. and Rabinovitch, P.S. (2001) Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96, 2839-2848
14. Murray, L., Sedo, A., Scott, M., McManus, D., Sloan, J.M., Hardie, L.J., Forman, D. and Wild, C.P. (2006) TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 55, 1390-1397
15. Rabinovitch, P.S., Longton, G., Blount, P.L., Levine, D.S. and Reid, B.J. (2001) Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am. J. Gastroenterol. 96, 3071-3083
16. Chao, D.L., Sanchez, C.A., Galipeau, P.C., Blount, P.L., Paulson, T.G., Cowan, D.S., Ayub, K., Odze, R.D., Rabinovitch, P.S. and Reid, B.J. (2008) Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with barrett's esophagus: a long-term prospective study. Clin. Cancer Res. 14, 6988-6995
17. Sirieix, P.S., O'Donovan, M., Brown, J., Save, V., Coleman, N. and Fitzgerald, R.C. (2003) Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin. Cancer Res. 9, 2560-2566
18. Lao-Sirieix, P., Lovat, L. and Fitzgerald, R.C. (2007) Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin. Cancer Res. 13, 659-665
19. Dahlberg, P.S., Ferrin, L.F., Grindle, S.M., Nelson, C.M., Hoang, C.D. and Jacobson, B. (2004) Gene expression profiles in esophageal adenocarcinoma. Ann. Thorac. Surg. 77, 1008-1015
20. Wang, S., Zhan, M., Yin, J., Abraham, J.M., Mori, Y., Sato, F., Xu, Y., Olaru, A., Berki, A.T., Li, H. et al. (2006) Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 25, 3346-3356
21. Breton, J., Gage, M.C., Hay, A.W., Keen, J.N., Wild, C.P., Donnellan, C., Findlay, J.B. and Hardie, L.J. (2008) Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J. Proteome Res. 7, 1953-1962
22. Schulmann, K., Sterian, A., Berki, A., Yin, J., Sato, F., Xu, Y., Olaru, A., Wang, S., Mori, Y., Deacu, E. et al. (2005) Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24, 4138-4148
23. Jin, Z., Cheng, Y., Gu, W., Zheng, Y., Sato, F., Mori, Y., Olaru, A.V., Paun, B.C., Yang, J., Kan, T. et al. (2009) A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 69, 4112-4115
24. Moons, L.M., Kusters, J.G., van Delft, J.H., Kuipers, E.J., Gottschalk, R., Geldof, H., Bode, W.A., Stoof, J., van Vliet, A.H., Ketelslegers, H.B. et al. (2008) A pro-inflammatory genotype predisposes to Barrett's esophagus. Carcinogenesis 29, 926-931
25. di Martino, E., Hardie, L.J., Wild, C.P., Gong, Y.Y., Olliver, J.R., Gough, M.D. and Bird, N.C. (2007) The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet. Med. 9, 341-347
26. Casson, A.G., Zheng, Z., Evans, S.C., Veugelers, P.J., Porter, G.A. and Guernsey, D.L. (2005) Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis 26, 1536-1541
27. Hennig, E.E., Mikula, M., Orlowska, J., Jarosz, D., Bielasik, A., Regula, J. and Ostrowski, J. (2008) Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus. J. Mol. Med. 86, 233-242
28. Overholt, B.F., Lightdale, C.J., Wang, K.K., Canto, M.I., Burdick, S., Haggitt, R.C., Bronner, M.P., Taylor, S.L., Grace, M.G. and Depot, M. (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest. Endosc. 62, 488-498
29. Overholt, B.F., Wang, K.K., Burdick, J.S., Lightdale, C.J., Kimmey, M., Nava, H.R., Sivak, Jr, M.V., Nishioka, N., Barr, H., Marcon, N. et al. (2007) Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest. Endosc. 66, 460-468
30. Prasad, G.A., Wang, K.K., Halling, K.C., Buttar, N.S., Wongkeesong, L.M., Zinsmeister, A.R., Brankley, S.M., Fritcher, E.G., Westra, W.M., Krishnadath, K.K. et al. (2008) Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 135, 370-379
31. Prasad, G.A., Wang, K.K., Halling, K.C., Buttar, N.S., Wongkeesong, L.M., Zinsmeister, A.R., Brankley, S.M., Westra, W.M., Lutzke, L.S., Borkenhagen, L.S. and Dunagan, K. (2008) Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer 113, 470-476
32. Kim, M.K., Cho, K.J., Kwon, G.Y., Park, S.I., Kim, Y.H., Kim, J.H., Song, H.Y., Shin, J.H., Jung, H.Y., Lee, G.H. et al. (2008) ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur. J. Cancer 44, 54-60
33. Heeren, P.A., Kloppenberg, F.W., Hollema, H., Mulder, N.H., Nap, R.E. and Plukker, J.T. (2004) Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res. 24, 2579-2583
34. Imdahl, A., Bognar, G., Schulte-Monting, J., Schoffel, U., Farthmann, E.H. and Ihling, C. (2002) Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur. J. Cardiothorac. Surg. 21, 657-663
35. Abdel-Latif, M.M., O'Riordan, J., Windle, H.J., Carton, E., Ravi, N., Kelleher, D. and Reynolds, J.V. (2004) NF-κB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann. Surg. 239, 491-500
36. Xi, H., Baldus, S.E., Warnecke-Eberz, U., Brabender, J., Neiss, S., Metzger, R., Ling, F.C., Dienes, H.P., Bollschweiler, E., Moenig, S. et al. (2005) High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin. Cancer Res. 11, 8341-8347
37. Brabender, J., Vallbohmer, D., Grimminger, P., Hoffmann, A.C., Ling, F., Lurje, G., Bollschweiler, E., Schneider, P.M., Holscher, A.H. and Metzger, R. (2008) ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J. Gastrointest. Surg. 12, 1815-1821
38. Grimminger, P., Vallbohmer, D., Hoffmann, A., Schulte, C., Bollschweiler, E., Schneider, P.M., Holscher, A.H., Metzger, R. and Brabender, J. (2009) Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. J. Surg. Oncol. 100, 447-451
39. Wu, X., Gu, J., Wu, T.T., Swisher, S.G., Liao, Z., Correa, A.M., Liu, J., Etzel, C.J., Amos, C.I., Huang, M. et al. (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J. Clin. Oncol. 24, 3789-3798
40. Alakus, H., Warnecke-Eberz, U., Bollschweiler, E., Monig, S.P., Vallbohmer, D., Brabender, J., Drebber, U., Baldus, S.E., Riemann, K., Siffert, W. et al. (2009) GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics J. 9, 202-207
41. Dragovich, T. and Campen, C. (2009) Anti-EGFR-targeted therapy for esophageal and gastric cancers: an evolving concept. J. Oncol. 2009, 804108
42. Villanacci, V., Rossi, E., Grisanti, S., Bassotti, G., Ferrari, V.D., Missale, G., Minelli, L., Cengia, P., Marini, G. and Cestari, R. (2008) Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol. Dietol. 54, 347-353
43. Chao, D.L., Maley, C.C., Wu, X., Farrow, D.C., Galipeau, P.C., Sanchez, C.A., Paulson, T.G., Rabinovitch, P.S., Reid, B.J., Spitz, M.R. and Vaughan, T.L. (2006) Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Cancer Epidemiol. Biomarkers Prev. 15, 1935-1940
44. Xing, J., Ajani, J.A., Chen, M., Izzo, J., Lin, J., Chen, Z., Gu, J. and Wu, X. (2009) Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev. Res. 2, 459-465
45. Bremnes, R.M., Sirera, R. and Camps, C. (2005) Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49, 1-12
46. Sun, L.C., Chu, K.S., Cheng, S.C., Lu, C.Y., Kuo, C.H., Hsieh, J.S., Shih, Y.L., Chang, S.J. and Wang, J.Y. (2009) Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer 9, 288
47. Eisenberger, C.F., Stoecklein, N.H., Jazra, S., Hosch, S.B., Peiper, M., Scheunemann, P., Am Esch, J.S. and Knoefel, W.T. (2006) The detection of oesophageal adenocarcinoma by serum microsatellite analysis. Eur. J. Surg. Oncol. 32, 954-960
48. Hoffmann, A.C., Vallbohmer, D., Prenzel, K., Metzger, R., Heitmann, M., Neiss, S., Ling, F., Holscher, A.H., Schneider, P.M. and Brabender, J. (2009) Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J. Cancer Res. Clin. Oncol. 135, 1231-1237
49. Hammoud, Z.T., Dobrolecki, L., Kesler, K.A., Rahmani, E., Rieger, K., Malkas, L.H. and Hickey, R.J. (2007) Diagnosis of esophageal adenocarcinoma by serum proteomic pattern. Ann. Thorac. Surg. 84, 384-392
50. Mechref, Y., Hussein, A., Bekesova, S., Pungpapong, V., Zhang, M., Dobrolecki, L.E., Hickey, R.J., Hammoud, Z.T. and Novotny, M.V. (2009) Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J. Proteome Res. 8, 2656-2666